- Home
- UNB vs ABOS Comparison
UNB vs ABOS Comparison
Compare UNB & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UNB | ABOS |
|---|---|---|
| Founded | 1891 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.6M | 113.9M |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UNB | ABOS |
|---|---|---|
| Price | $23.75 | $2.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 11.2K | ★ 151.0K |
| Earning Date | 01-14-2026 | 11-12-2025 |
| Dividend Yield | ★ 6.07% | N/A |
| EPS Growth | ★ 27.30 | N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $52,533,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.61 | ★ N/A |
| Revenue Growth | ★ 13.25 | N/A |
| 52 Week Low | $20.65 | $0.86 |
| 52 Week High | $36.00 | $2.46 |
Technical Indicators
Market Signals| Indicator | UNB | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 57.58 | 54.47 |
| Support Level | $22.96 | $1.87 |
| Resistance Level | $23.95 | $2.19 |
| Average True Range (ATR) | 0.68 | 0.14 |
| MACD | 0.17 | 0.03 |
| Stochastic Oscillator | 66.82 | 66.67 |
Price Performance
Historical ComparisonAbout UNB Union Bankshares Inc.
Union Bankshares Inc operates as a community bank in the financial services industry. It offers retail and commercial banking services to its customers through its branches, ATMs, telebanking, and internet banking systems. The company provides retail banking services to individuals and commercial banking services to small and medium-sized corporations, partnerships, and sole proprietorships, as well as nonprofit organizations, local municipalities, and school districts within its market area. In addition, it also offers fiduciary and asset management services through its Asset Management Group.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.